Literature DB >> 17460454

Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases.

Francoise Galateau-Sallé1, Richard Attanoos, Allen R Gibbs, Louise Burke, Philippe Astoul, Patrick Rolland, Anabelle Gilg Soit Ilg, Jean Claude Pairon, Patrick Brochard, Hugues Begueret, Jean Michel Vignaud, Keith Kerr, Guy Launoy, Ellen Imbernon, Marcel Goldberg.   

Abstract

The lymphohistiocytoid variant of diffuse malignant mesothelioma is rare with very few cases described in the literature. It is characterized by mesothelial cells with a histiocytelike appearance and an associated dense lymphoid infiltrate. We studied clinicopathologic features and immunohistochemical patterns of a series of 22 cases. The histiocytelike cells had a mesothelial immunophenotype: AE1/AE3 (100%), calretinin (100%), CK5/6 (46%), and EMA (52%). The prominent lymphoid component showed a cytotoxic T-cell immunophenotype. Prognosis was similar to that of a large series of epithelioid diffuse malignant mesotheliomas. Formely, it was classified within the sarcomatoid type. We suggest that it should be reclassified as an epithelioid variant because of its similar behavioural characteristics. There was no evidence of Epstein-Barr virus-related infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17460454     DOI: 10.1097/PAS.0b013e31802baad7

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  3 in total

Review 1.  Pleural mesothelioma classification update.

Authors:  Mary Beth Beasley; Francoise Galateau-Salle; Sanja Dacic
Journal:  Virchows Arch       Date:  2021-01-21       Impact factor: 4.064

2.  Lymphangiomatoid pattern in diffuse malignant mesothelioma of the pleura: a report of six cases.

Authors:  Ruchira Ruangchira-urai; Eugene J Mark
Journal:  Virchows Arch       Date:  2009-07-18       Impact factor: 4.064

Review 3.  When the Diagnosis of Mesothelioma Challenges Textbooks and Guidelines.

Authors:  Giulio Rossi; Fabio Davoli; Venerino Poletti; Alberto Cavazza; Filippo Lococo
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.